- Home
- ANVS vs RAND Comparison
ANVS vs RAND Comparison
Compare ANVS & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANVS | RAND |
|---|---|---|
| Founded | 2008 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 32.4M |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ANVS | RAND |
|---|---|---|
| Price | $2.82 | $11.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 306.0K | 4.2K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | ★ 10.21% |
| EPS Growth | ★ 39.39 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $10.05 |
| 52 Week High | $5.50 | $21.30 |
Technical Indicators
Market Signals| Indicator | ANVS | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 50.07 |
| Support Level | $2.29 | $10.31 |
| Resistance Level | $2.98 | $12.50 |
| Average True Range (ATR) | 0.20 | 0.49 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 69.44 | 36.61 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.